High-sensitivity C-reactive protein (hs-CRP) is a blood test that measures very low concentrations of C-reactive protein, an acute-phase protein produced by the liver in response to inflammation. Because atherosclerosis is in part an inflammatory process, hs-CRP is used as a biomarker of systemic low-grade inflammation and as an adjunct in cardiovascular risk assessment. Widely used clinical cut-points classify hs-CRP below 1, 1 to 3, and above 3 mg/L as lower, average, and higher relative cardiovascular risk. Unlike the standard CRP assay used to detect overt infection or autoimmune flares, the high-sensitivity assay resolves the small differences relevant to long-term risk stratification in otherwise healthy people.
Across large prospective cohorts and meta-analyses, higher hs-CRP is consistently associated with increased risk of coronary heart disease, stroke, cardiovascular and non-vascular mortality, and with aging-related states such as frailty and dementia; a landmark randomized trial (JUPITER) found that treating people with elevated hs-CRP but normal LDL cholesterol reduced cardiovascular events, and a second trial (CANTOS) showed that anti-inflammatory therapy targeting the pathway upstream of CRP lowered recurrent events in patients selected by elevated hs-CRP, establishing the test as a marker of targetable residual inflammatory risk. However, the evidence has important limits: Mendelian randomization studies indicate CRP itself is unlikely to be a causal factor in heart disease, and some analyses conclude it adds only modest predictive value beyond traditional risk factors for most individuals. CRP is also non-specific, rising with infection, obesity, smoking and many other conditions, so a single value cannot identify the source of inflammation and an elevated reading should be repeated once any acute illness has resolved. This body of evidence describes the C-reactive protein biomarker and the hs-CRP measurement in general, not any specific commercial testing product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“elevated inflammatory index was significantly associated with cardiovascular disease incidence and mortality”
“hs-CRP was the strongest univariate predictor of the risk of cardiovascular events”
“adjusted hazard ratio 1.70 for high-sensitivity CRP over 30 years”
“In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.”
“CRP concentration has continuous associations with the risk of coronary heart disease, ischaemic stroke, vascular mortality, and death from several cancers and lung disease that are each of broadly similar size.”
“C-reactive protein (CRP), a blood marker of inflammation and a hallmark of the acute-phase response, has been shown to be a powerful and specific predictor of cardiovascular event risk in populations of otherwise healthy persons.”
Research describes the active mechanism and is not a claim about this specific product.
Across large prospective cohorts and meta-analyses, lower grip strength is consistently…
Across large studies, dysregulated cortisol patterns track with worse health: a…
Large prospective cohorts and meta-analyses consistently link higher serum GGT, even…
Higher fasting insulin and HOMA-IR reflect greater insulin resistance, a central feature…
Yes — its active compound is linked to 19 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.